Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 770 participants.
Also called NCT03351478
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 770 participants
- Sponsor
- Registry
-
NCT03351478 -
2016-001803-22
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Canada, Czechia, France, Italy, Latvia, Mexico, Russia, Slovakia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03351478. Randomized; double masking; primary purpose treatment. Start 2017-11-27 (actual); primary completion 2019-05-16 (actual). Results posted on 2021-05-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
- Acronym
- SOTA-EMPA
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sotagliflozin
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Lead sponsor
- Lexicon Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct03351478- Content hash
338de4d0fbbf72842f7a61bcfefeb30e65238b5dc08c4614d26be2356c3da002